Carl Zeiss Meditec in Pivotal Point Check: Analysts Excited - Robot-Assisted Ophthalmic Laser Device Visumax 800 Paves the Way in China!
Reading Time: 3 minutes
Analyst optimism continues to drive the recovery rally at Carl Zeiss. Visumax 800 approval in China is expected to improve order intake. For Hauck & Aufhäuser, the shares of the medical technology manufacturer are among the "Top Picks" for 2025. The new analyst optimism continues to drive the recovery rally at Carl Zeiss. On January 23, 2025, the analysis house Equita issued a buy recommendation for the medical technology manufacturer, followed by the British bank HSBC. Equita set a price target of 60 euros. In mid-January, the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
